Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019
By
- AMS
posted
Aug 11, 2021 09:24 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
- AMS
Added Oct 23, 2020
Blog Entry
Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review
- AMS
Added Sep 25, 2020
Blog Entry
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
- AMS
Added Mar 23, 2021
Blog Entry
Language proficiency and biologics access: a population study of psoriasis patients in the United States
- AMS
Added Sep 15, 2020
Blog Entry
United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors
- AMS
Added Feb 20, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic